Perspectives de thérapie génique de la resténose

Medecine/Sciences

Volumn 12, Issue 1, 1996, Pages 47-55

  Feldman, Laurent J ^a   Steg, Ph Gabriel ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES; HERPESVIRIDAE;

GANCICLOVIR; PROTEIN; THYMIDINE KINASE;

ADENOVIRUS; ARTICLE; ATHEROSCLEROSIS; CARDIOLOGY; CELL DIVISION; CELL PROLIFERATION; CELLULAR IMMUNITY; CORONARY ARTERY; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HEALTH CARE COST; HUMORAL IMMUNITY; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; SMOOTH MUSCLE; TOXICITY; TRANSGENE;

EID: 0030045092     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/602     Document Type: Article

References (53)

1. Feldman LJ, Riessen R, Steg PG. Prevention of restenosis after coronary angioplasty: towards a molecular approach? Fundam Clin Pharmacol 1995; 9: 8-16.
2. Isner JM, Feldman LJ. Gene therapy for arterial disease. Lancet 1994; 344: 1653-4.
3. Nabel EG. Gene therapy for cardiovascular disease. Circulation 1995; 91: 541-8.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
5. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208-15.
6. Schwartz SM, de Blois D, O'Brien ERM. The intima. Soil for atherosclerosis and restenosis. Circ Res 1995; 77: 445-65.
7. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267: 1782-8.
8. Marx J. How p53 suppresses cell growth. Science 1993; 262: 1644-5.
9. Furukawa Y, DeCaprio JA, Freedman A, et al. Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci USA 1990; 87: 2770-4.
10. Gorski DH, LePage DF, Patel CV, Copeland NG, Jenkins NA, Walsh K. Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol 1993; 13: 3722-33.
11. Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM. Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995; 76: 996-1002.
12. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994; 89: 2809-15.
13. Gertz SD, Gimple LW, Banai S, Ragosta M, Powers ER, Roberts WC, Perez LS, Sarembock IJ. Geometric remodeling is not the principal pathogenetic process in restenosis after balloon angioplasty. Evidence from correlative angiographic-histomorphometric studies of atherosclerotic arteries in rabbits. Circulation 1994; 90: 3001-8.
14. Mulligan RC. The basic science of gene therapy Science 1993; 260: 926-32.
15. Riessen R, Isner JM. Prospects for site-specific delivery of pharmacologic and molecular therapies. J Am Coll Cardiol 1994; 23: 1234-44.
16. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990; 249: 1285-8.
17. Takeshita S, Gal D, Leclerc G, Pickering JG, Riessen R, Weir L, Isner JM. Increased gene expression after liposome-mediated arterial gene transfer associated with intimal smooth muscle cell proliferation. In vitro and in vivo findings in a rabbit model of vascular injury. J Clin Invest 1994; 93: 652-61.
18. Riessen R, Rahimizadeh H, Takeshita S, Gal D, Barry JJ, Isner JM. Successful vascular gene transfer using a hydrogel coated balloon angioplasty catheter. Hum Gene Ther 1993, 4: 749-58.
19. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993; 72: 1132-8.
20. Steg PG, Feldman LJ, Scoazec J-Y, Tahlil O, Barry JJ, Boulechfar S, Ragot T, Isner JM, Perricaudet M. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation 1994; 90: 1648-56.
21. Feldman LJ, Steg PG, Zheng LP, Chen D, Kearney M, McGarr SE, Barry JJ, Dedieu J-F, Perricaudet M, Isner JM. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest 1995; 95: 2662-71.
22. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992; 90: 626-30
23. Berkner KL. Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol 1992; 158: 39-66.
24. Schulick AH, Dong G, Newman KD, Virmani R, Dichek DA. Endothelium-specific in vivo gene transfer. Circ Res 1995; 77: 475-85.
25. Casscels W, Willerson JT. Amphotropic but not atherotropic: another caveat for adenoviral gene therapy. J Clin Invest 1995; 95: 2425-6.
26. Dedieu JF, Vigne E, Orsini C, Denefle P, Perricaudet M, Yeh P. Improvement of adenoviral vectors for human gene therapy: E1 and E4 deleted recombinant adenoviruses. In: March KL, ed. Gene transfer in cardiovascular biology: experimental approaches and therapeutic implications. Dordrecht: Kluwer, 1996 (sous presse).
27. Harats D, Kurihara H, Belloni P, Oakley H, Ziober A, Ackley D, Cain G, Kurihara Y, Lawn R, Sigal E. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest 1995; 95: 1335-44.
28. Wu GY, Zhan P, Sze LL, Rosenberg AR, Wu CH. Incorporation of adenovirus into a ligand-based DNA carrier sytem results in retention of original receptor specificity and enhances targeted gene expression. J Biol Chem 1994; 269: 11542-6.
29. Feldman LJ, Steg PG, Zheng LP, Barry JJ, Perricaudet M, Isner JM. Efficient percutaneous adenovirus-mediated arterial gene transfer using a channeled angioplasty balloon catheter. Circulation 1994; 90: I-20.
30. Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries. Optimization and evaluation of acute toxicity. Circulation 1995; 91: 2407-14.
31. Pastore C, Feldman LJ, Perricaudet M, Steg PG. Intraluminal delivery of a pluronic gel enhances adenovirus-mediated arterial gene transfer: a morphometric study. Circulation 1994; 90: I-517.
32. Moolten F. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-81.
33. Chen S-H, Shine HD, Goodman JC, Grossman RG, Woo SLC. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-7.
34. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-4.
35. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 1994; 91: 10732-6.
36. Tahlil O, Branellec D, Aubailly N, Dedieu JF, Lefeuvre C, Ratet N, Caillaud J-M, Barry IJ, Perricaudet M, Feldman LJ, Denèfle P, Steg PG. Reduction of restenosis after angioplasty by gene therapy with HSV-tk and ganciclovir. Results from a double injury model in the hypercholesterolemic rabbit. Circulation 1995; 92: I-295.
37. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-22.
38. Branelec D, Pastore C, Dedieu JF, Smith R, Berthelot K, Feldman L, Benoît P, Isner JM, Walsh K, Denèfle P. A recombinant adenovirus encoding gax can efficiently block vascular smooth muscle cell proliferation. Circulation 1995; 92: I-634.
39. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7
40. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12
41. Hamon M, Vallet B, Bauters C, Wernert N, McFadden EP, Lablanche J-M, Dupuis B, Bertrand ME. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependant acethylcholine-induced relaxation after arterial injury. Circulation 1994; 90: 1357-62.
42. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-41.
43. Epstein SE, Speir E, Finkel T. Do antisense approaches to the problem of restenosis make sense? Circulation 1993; 88: 1351-4
44. Bennett MR, Schwartz SM. Antisense therapy for angioplasty restenosis. Some critical considerations. Circulation 1995; 92: 1981-93.
45. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70.
46. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan G. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994; 93: 820-8.
47. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8
48. Simons M, Edelman ER, Rosenberg RD. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest 1994; 93: 2351-6.
49. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leynen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994; 93: 1458-64.
50. Woolf TM, Melton DA, Jennings CGB. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci USA 1992, 89. 7305-9.
51. Villa AE, Guzman LA, Poptic EJ, Labhasetwai V, D'Souza S, Farell CL, Plow EF, Levy RJ, DiCorletto PE, Topol EJ. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and reponse to vessel wall injury. Circ Res 1995; 76: 505-13.
52. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995. 92: 58559.
53. Marshall E. Gene therapy's growing pains. Science 1995; 269: 1050-5.